Our Expert in Germany

GOLD

Anke Krebs

GOLD

Stopping Parallel Imports of Medicines in Germany 2026: Legal Options for Pharma Companies

By Global Law Experts

– posted 2 hours ago

Parallel imports germany pharma enforcement remains a significant commercial priority in 2026, as ongoing German pharmacy and healthcare reform reshapes distribution, reimbursement and pricing incentives across the market. For brand owners and in-house counsel, the practical question is no longer whether parallel importers will target a product, but how quickly and effectively a rights holder can respond when they do. This guide takes a decisive, practitioner-oriented approach: it explains the current drivers, sets out the legal foundations, and gives you a clear four-step decision framework with a side-by-side comparison of remedies so you can choose the right tool for the facts in front of you.

Where the law genuinely permits relief, we tell you which route to take, and where it does not, we say so plainly.

Who this guide is for: pharmaceutical brand owners and in-house counsel evaluating how to stop or limit parallel imports into Germany in 2026, balancing speed, cost and enforceability. Treat all timing and cost figures as typical/indicative and confirm current local practice and the current legislative position with German counsel before acting.

Reform context in 2026 and why it affects parallel import risk

Ongoing reform to German pharmacy distribution, dispensing and reimbursement is an important near-term driver of parallel import risk for brand owners supplying the German market. By adjusting the economics of pharmacy distribution, dispensing and reimbursement, such reform can alter the margins and arbitrage opportunities that parallel importers rely on. For any team managing parallel imports germany pharma exposure, understanding these mechanics is the starting point for a sensible enforcement strategy. Because the detail and timing of pharmacy-law reform proposals continue to develop, brand teams should verify the current status of any legislative measure directly with the German Federal Ministry of Health (Bundesministerium für Gesundheit) and with counsel before relying on it.

Reform levers that affect distribution and pricing

Pharmacy-law reform proposals typically touch the levers that determine where a packet of medicine is most profitable to sell. Changes to dispensing economics, pharmacy remuneration and the structure of reimbursement can change the price differential between Germany and lower-priced EEA markets. Where those differentials widen, so does the commercial attraction of sourcing genuine product abroad and reselling it in Germany. Brand teams should review any consolidated reform text and the explanatory materials published by the Bundesministerium für Gesundheit to confirm which provisions apply to their product category.

How those changes affect incentives for arbitrage and parallel importers

Parallel import is, at its core, an arbitrage business: importers buy where prices are low and sell where they are high. When a reform shifts German pricing or dispensing incentives, it recalibrates every importer’s calculation. The likely practical effect, as industry observers expect, is a sharper focus by importers on high-value, high-differential products, particularly originator medicines with strong German demand. That means the products most worth protecting are often precisely those most likely to attract parallel import activity, and the window between a reform taking effect and importers responding can be short.

Quick compliance note for brand teams

Before pursuing enforcement, confirm your own distribution contracts, supply allocations and pricing structures are consistent with the current regulatory framework. A clean compliance position strengthens every remedy discussed below and removes arguments an importer might otherwise raise against you.

Legal foundations: exhaustion doctrine, trademarks, patents and SPCs in Germany

Every parallel imports germany pharma decision turns first on one question: have the relevant intellectual property rights been exhausted? The answer determines whether you have a viable claim at all. Below are the doctrines that structure the analysis, grounded in EU and German law.

EU and German exhaustion doctrine, test and precedent

The exhaustion doctrine germany applies within the European Economic Area: once a product protected by an IP right has been placed on the EEA market by the rights holder or with their consent, the rights holder cannot generally use that right to prevent further resale of those genuine goods, including into Germany. This principle is well established in the case law of the Court of Justice of the European Union and reflected in German Federal Court of Justice (Bundesgerichtshof) practice.

The crucial consequence is blunt: if the goods are genuine and were lawfully placed on the EEA market by you or with your consent, the default position is that you cannot stop their resale in Germany on the basis of exhaustion alone.

The analysis does not end there, however. Exhaustion is subject to recognised exceptions, most importantly where a parallel importer repackages or relabels the product in a way that affects the condition of the goods or risks consumer confusion, or where the goods were never lawfully placed on the EEA market by the rights holder. These exceptions are where enforcement opportunities live. Each case requires a careful factual and legal review against CJEU jurisprudence and current German practice; do not assume either exhaustion or its exceptions apply without examining the specific product, packaging and supply chain.

Trade mark law: exhaustion and its exceptions

Trade mark rights are frequently the most practical route to stop parallel imports because packaging, labelling and brand presentation are where importers most often overstep. Under EU trade mark law (including the EU Trade Mark Regulation) and the German Trade Mark Act (Markengesetz), a rights holder cannot oppose the use of their mark for genuine goods placed on the EEA market with consent, the trade mark equivalent of exhaustion. But that defence falls away where there are legitimate reasons to oppose further commercialisation, classically where the condition of the goods has been changed or impaired after being put on the market, or where repackaging damages the mark’s reputation or creates confusion.

Pharmaceutical trademark enforcement germany therefore often succeeds precisely in the repackaging and relabelling scenarios so common in the parallel import trade. The CJEU has developed detailed conditions governing when a trade mark owner may oppose repackaged parallel imports of pharmaceuticals, and these should be checked against the current case law in each matter.

Patent and SPC basics relevant to parallel imports

Patent and supplementary protection certificate (SPC) rights offer a different and often stronger lever. Patent exhaustion, like trade mark exhaustion, applies only once the rights holder has lawfully placed the product on the EEA market. Where goods fall within a valid patent or SPC and were not placed on the market by or with the consent of the rights holder, the SPC impact on parallel imports can be decisive. SPCs, governed by Regulation (EC) No 469/2009, extend exclusivity for patented active ingredients beyond the base patent term, and can be enforced against imports falling within their scope, subject always to exhaustion rules and the precise scope of the claims.

For products still within SPC protection, this is frequently the most robust basis for relief.

Four-step decision framework for parallel imports germany pharma: choose the right remedy

Deciding how to respond is a structured exercise, not a reflex. The following four steps move you from detection to a reasoned remedy choice, and the comparison table below lets you weigh the options side by side.

Step 1: Identify product, packaging and country of origin

Secure samples of the suspect goods. Document the packaging, batch numbers, language of labelling, repackaging evidence and apparent country of first sale. The country of origin determines whether exhaustion is even in play; the packaging determines whether a repackaging-based exception is available.

Step 2: Legal test matrix (exhaustion, repackaging, infringement)

Run the facts through three sequential questions. First, were the goods placed on the EEA market by you or with your consent? If no, your IP rights are likely not exhausted and you have a strong claim. If yes, move to the second question: has the importer repackaged, relabelled or altered the goods in a way that impairs their condition or causes consumer confusion? If yes, the exhaustion defence may be overcome on trade mark grounds. Third, do the goods fall within a valid patent or SPC that was never exhausted for these particular units? If yes, patent or SPC enforcement is available.

Question	If “No”	If “Yes”
Placed on EEA market by rights holder / with consent?	Rights not exhausted, strong claim (patent/SPC/trade mark)	Exhaustion presumptively applies, go to next test
Repackaged / relabelled / condition impaired?	Trade mark relief unlikely on this ground	Exhaustion defence may be overcome, trade mark claim viable
Within valid, unexhausted patent/SPC scope?	No patent/SPC route	Patent/SPC enforcement available, often strongest route

Step 3: Practical remedies checklist

With the legal test complete, match it to a remedy: customs detention at the border, a cease-and-desist letter, a preliminary injunction (einstweilige Verfügung), a full infringement action, contractual enforcement against your own counterparties, or regulatory and criminal reporting. In many urgent cases the combination of a customs application and a preliminary injunction delivers the fastest meaningful relief.

Step 4: Cost, time and risk assessment

Weigh speed against enforceability and exposure. Border and injunction measures are fast but require strong, ready evidence and may expose you to security or counterclaims. Full litigation is slower but can deliver more durable outcomes and damages. The table below sets out the trade-offs so you can decide rather than deliberate.

**Compare remedies to stop parallel imports in Germany (2026)**
Remedy	Legal basis	Speed (typical)	Likely success (if facts align)	Cost range	Key evidence required	Practical limits
Customs detention/seizure	EU customs IP enforcement regime (Regulation (EU) No 608/2013) & German customs procedures	Days–weeks	High	Low–medium	Commercial invoices, trade marks, product origin, import declaration	Only at border; intra-EEA movements of genuine goods may not qualify
Preliminary injunction (einstweilige Verfügung)	German Code of Civil Procedure (ZPO) injunction practice before the competent court	Days–weeks (ex parte possible)	High	Medium–high	Samples, invoices, proof of distribution channels, urgency/risk of harm	Needs strong evidence; countersecurity possible
Trade mark infringement suit	German Trade Mark Act / EU trade mark law	Months–years	Medium–high	Medium–high	Brand use evidence, packaging, likelihood of confusion	Exhaustion defence may apply to genuine goods
Patent infringement / SPC enforcement	German Patent Act / SPC Regulation (EC) No 469/2009 (and, where applicable, the Unified Patent Court regime)	Months–years (injunction faster if urgent)	High	High	Technical claims comparison, lab analysis, product samples	Exhaustion applies only after lawful EEA placing by rights holder
Contractual & distribution measures	Contract law, supply agreements	Variable	High (vs counterparties)	Low–medium	Contract copies, supply chain records	Only binds contractual counterparties
Criminal enforcement & regulatory reporting	Relevant criminal provisions; regulatory reporting to competent authorities	Variable	Low–medium (deterrent)	Low	Evidence of illegal imports or false labelling	Rarely produces immediate relief

Our recommendation: for imminent shipments, consider leading with a customs application plus a preliminary injunction where the facts clearly support one. For ongoing, structural infringement, pursue a patent/SPC action where the product is still protected, and a trade mark action where repackaging or confusion is the core wrong. Use contractual levers against your own supply chain in parallel. Treat criminal reporting as a deterrent, not a primary remedy.

Tactical playbooks

The framework tells you what to choose; the playbooks tell you how to execute. These are the workflows experienced practitioners run when parallel imports germany pharma risk crystallises.

Rapid response playbook (imminent shipments / at-port detentions)

Speed is important when goods are about to cross the border. Run these steps in order:

Detection. Act the moment you learn of an inbound shipment, from a distributor tip-off, market surveillance or a customs alert.
Evidence preservation. Photograph packaging and labelling, secure the import declaration and commercial invoices, and record batch numbers and the apparent country of first sale before anything is altered.
Customs application. File or activate your application for customs action (under the EU customs IP enforcement regime) so German customs (Zoll) can detain goods suspected of infringing your IP. Having a standing application on file can shorten the response time; note that the border customs regime is primarily directed at goods entering the EU and may not capture the intra-EEA movement of genuine exhausted goods, confirm applicability with counsel.
Sample testing. Obtain samples for forensic comparison against your genuine product, formulation, packaging integrity and labelling.
Emergency injunction. Where the facts are clear, prepare an ex parte preliminary injunction application. Assemble samples, invoices, proof of distribution channels and a clear articulation of urgency so the court can act quickly.

Keep a ready “rapid response pack”: a document checklist, a template labelling-comparison photo sheet, and pre-drafted customs and injunction paperwork. The difference between stopping a shipment and watching it clear is often preparation.

Litigation playbook: trademarks vs patents vs SPCs

Choosing the claim is a central strategic decision, and the right answer depends on the nature of the wrong rather than on habit.

Choose a trade mark claim when the importer has repackaged, relabelled or co-branded the product, changed its condition, or created a risk of consumer confusion. These are the classic grounds on which the exhaustion defence may be overcome, and pharmaceutical trademark enforcement germany is well suited to them. Trade mark actions are also attractive where you lack patent protection but retain a strong, registered brand.
Choose a patent or SPC claim when the goods fall within valid, unexhausted technical claims, when there is a genuine manufacturing-origin or formulation difference, or when the units were never lawfully placed on the EEA market by you. Where SPC protection remains in force, the SPC impact on parallel imports can be a strong and durable basis for relief.
Run both in cross-disciplinary cases. Where repackaging and patent/SPC infringement coincide, a combined team maximises your options and lets you pursue the fastest available route to an injunction while the broader action proceeds.

On cross-border coordination: a German injunction binds conduct in Germany, but parallel importers often operate across several EEA states. Coordinate enforcement with counsel in the source and transit jurisdictions, and consider how a German win can be leveraged commercially and procedurally elsewhere. Where unitary patents are involved, the Unified Patent Court may provide a route to broader cross-border relief, assess this with specialist counsel. Throughout, anticipate the exhaustion defence and the repackaging exception, and build your evidence strategy to meet them head-on rather than reactively.

Administrative and regulatory levers

Beyond the courts, regulatory bodies provide complementary pressure. The German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) oversees aspects of product authorisation, pharmacovigilance and labelling, and reporting non-compliant or falsely labelled imports can trigger regulatory scrutiny. German customs (Zoll) enforces border measures, and EU-level cooperation, including guidance from the European Union Intellectual Property Office on customs cooperation, supports coordinated action. These levers rarely deliver instant relief on their own, but they can strengthen the overall case and raise the cost of infringement for importers.

Settlement, licensing and grey-market management options

Litigation is not the only outcome worth pursuing. Commercial levers can resolve a parallel import problem more cheaply and durably than a judgment. Consider selective distribution systems that restrict who may handle your product, rigorous enforcement of supply agreements to cut off the source, and price-corridor strategies that reduce the arbitrage differential driving the trade, always within the bounds of EU and German competition law, which restricts measures that partition the single market. In some cases a negotiated licensing or supply arrangement with an importer converts an adversary into a controlled channel. Weigh these options alongside litigation rather than after it.

Evidence, lab work and expert proof

No remedy survives contact with a German court without disciplined evidence. For parallel imports germany pharma cases, the quality of your proof usually determines the outcome.

Forensic testing and chain-of-custody

Secure representative samples and preserve an unbroken chain of custody from acquisition to court. Use accredited laboratories for formulation and packaging analysis, document who handled each sample and when, and store exhibits in conditions that prevent degradation. A break in the chain of custody is one of the easiest ways for an opponent to discredit otherwise compelling technical evidence.

Proving repackaging, batch differences and labelling changes

For trade mark claims, demonstrate precisely how the importer altered the product: new outer packaging, over-stickered labels, removed or added leaflets, or changes that affect the product’s condition or create confusion. For patent and SPC claims, show the technical correspondence between the imported goods and your claims, supported by batch records and comparative analysis. Ensure foreign-language documents are accompanied by certified translations, German courts will generally expect them, and untranslated exhibits slow proceedings and weaken persuasion.

Costs, timelines and risks

A decision to enforce is a decision to spend, and realistic budgeting prevents stalled cases. The descriptions below are indicative; statutory fees in Germany are driven in part by the value in dispute (Streitwert) under the applicable fee legislation, and actual costs vary widely. Confirm current rates and procedural specifics with German counsel.

Ballpark cost ranges and security considerations

German lawyers’ fees vary with complexity and the value in dispute; technical patent and SPC matters sit at the higher end, while customs applications and straightforward cease-and-desist work are considerably cheaper. Customs measures are typically low-to-medium cost, preliminary injunctions medium-to-high, and full patent or SPC litigation high. When seeking a preliminary injunction, be prepared for the possibility that the court requires security (a bond) to protect the defendant against loss if the injunction later proves unjustified. Factor this into your cash-flow planning from the outset.

Enforcement risks: counterclaims, damages and reputation

Enforcement carries exposure. An importer may counterclaim, challenge the validity of your patent or SPC, or argue exhaustion. A preliminary injunction wrongly obtained can expose you to damages for loss caused to the defendant. There are also reputational and regulatory dimensions, aggressive enforcement that is seen to restrict access to affordable medicines can attract scrutiny, including under competition law. These risks do not counsel against enforcement; they counsel precise, well-evidenced action on strong facts, and candid advice on where the facts are weaker.

How to choose German counsel and litigation venue

The right team and venue materially affect speed and outcome. Choose deliberately.

When to instruct a Patentanwalt versus civil litigation counsel

For patent and SPC enforcement, instruct a German patent attorney (Patentanwalt) with genuine litigation experience alongside an attorney at law (Rechtsanwalt), as patent infringement litigation before the German courts is conducted by attorneys at law, typically working together with patent attorneys. For trade mark actions and civil injunctions, an experienced German litigator (Rechtsanwalt) is essential. For cross-disciplinary disputes combining repackaging and patent/SPC infringement, assemble a dual team so neither the technical nor the procedural dimension is neglected. Our hiring guidance: prioritise demonstrable pharma parallel-import experience and preliminary injunction track record over generalist credentials.

Venue choices and cross-border enforcement

Infringement actions and injunctions are typically pursued before a Regional Court (Landgericht) with designated IP competence, with escalation available to the Higher Regional Court (Oberlandesgericht) and, on points of law, ultimately the Federal Court of Justice (Bundesgerichtshof). Where unitary patents are concerned, the Unified Patent Court may be the appropriate forum. Choose a venue with relevant pharma and IP experience, and plan early for how a German order will be coordinated with enforcement in other EEA states where the importer operates.

For procurement, GLE’s hiring resources help you shortlist and compare firms: see our Pharmaceutical patent lawyers, Germany (checklist) and our Intellectual property lawyer, Germany (hire guide). For named expertise in cross-border pharma enforcement and SPC litigation, review the lawyer profile.

Practical checklist: immediate steps for brand teams

Detect early. Maintain market surveillance and distributor reporting so you learn of suspect shipments before they clear customs.
Preserve evidence. Photograph packaging, secure invoices and import declarations, and record batch numbers and country of first sale.
Consider a customs application. Where applicable, keep a standing application for customs action on file with German customs so detention can be triggered quickly.
Run the legal test. Apply the exhaustion, repackaging and patent/SPC questions to confirm you have a viable claim.
Send a pre-litigation notice. A targeted cease-and-desist can resolve clear-cut cases quickly and builds the record for an injunction.
Instruct the right counsel. Engage a Patentanwalt and/or litigator with pharma parallel-import experience before deadlines bite.
Prepare the injunction pack. Have samples, evidence and draft pleadings ready so you can move quickly, including ex parte where appropriate, when speed matters.

Conclusion and recommended next steps

For parallel imports germany pharma enforcement in 2026, the decisive factors are preparation, the right legal test and the right remedy for the facts. Start by confirming whether your IP rights are exhausted; if they are not, or if repackaging or SPC scope gives you an opening, act fast. Our recommended default for imminent shipments is a customs application combined with a preliminary injunction where the facts support one; for structural infringement, pursue patent/SPC relief where protection remains and trade mark relief where repackaging or confusion is the wrong. Build disciplined evidence, instruct experienced German counsel early, and coordinate across borders.

Ongoing pharmacy-law reform may widen the arbitrage window, brand teams that have their detection, evidence and remedy playbooks ready will be the ones best placed to stop parallel imports before they reach the shelf.

Need Legal Advice?

This article was produced by Global Law Experts. For specialist advice on this topic, contact Anke Krebs at dompatent, a member of the Global Law Experts network.

Sources

FAQs

Can I stop genuine medicines legally placed on sale elsewhere in the EU from being sold in Germany?

Often not. The exhaustion doctrine allows resale of genuine goods placed on the EEA market by the rights holder or with their consent. But exceptions, repackaging, trade mark infringement, or valid patent/SPC protection that was never exhausted, can permit relief. Each case requires factual and legal analysis against current case law.

When is a trademark claim preferable to a patent claim to stop parallel imports?

Use a trade mark claim when there is repackaging, labelling change or a risk of consumer confusion. Use a patent or SPC claim when the goods infringe valid technical claims or fall outside the legitimate supply chain. Where both apply, run them together.

How fast can customs stop a shipment of parallel-imported medicines?

If your evidence and customs application are in place, German customs can detain a suspect shipment quickly. Effective use depends on correctly filed applications and proof of your IP rights, and on whether the goods fall within the scope of the customs IP enforcement regime, note that the intra-EEA movement of genuine, exhausted goods may not qualify. Filing without preparation causes delay.

What is the role of SPCs in preventing parallel imports germany pharma risk?

SPCs extend exclusivity for patented active ingredients under Regulation (EC) No 469/2009 and can be enforced against imports that fall within the SPC’s protected scope, subject to exhaustion rules and the precise scope of the claims. For products still within SPC protection, this is frequently a strong basis for relief.

Do I need a German patent attorney to pursue urgent relief?

For patent and SPC enforcement, a Patentanwalt with litigation experience working alongside an attorney at law is usually advisable. For trade mark actions and civil injunctions, an experienced German litigator is essential. For cross-disciplinary cases, a dual team is the right choice.